A MediCom Oncology Site
This website uses cookies. By using our site you agree to our privacy policy
Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Contact Us
    • Accreditation
    • MediCom Worldwide, Inc.
  • Reference
    • What is Multiple Myeloma?
    • FAQ Library
    • Clinical Pearls Podcasts
    • COVID-19 Resource Center
  • CE Education
    • Developments in NDMM
    • Annual Meeting Highlights
    • Accredited E-Newsletter Series
    • Practice Essentials
  • Resources
    • Web Links
    • Newsletters
  • Highlights in Multiple Myeloma from the Annual ASCO and EHA 2022 Meetings
  • Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
  • What is Multiple Myeloma
  • The Use of Biosimilars in Hematology/Oncology Practice
  • Visit Our FAQ Library Now!
  • Practice Essentials in Multiple Myeloma
Highlights in Multiple Myeloma from the Annual ASCO and EHA 2022 Meetings

Joshua Richter, MD

The Use of Biosimilars in Hematology/Oncology Practice

Dr. Charles Bennett, Dr. Marc Fishman, and Dr. Kevin Knopf

Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?

Saad Z. Usmani, MD, FACP




What has been the overall impact of safety and efficacy in four-drug regimens compared to three-drug regimens?

Sagar Lonial, MD, FACP
FAQ

Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes

Sagar Lonial, MD, FACP and Saad Z. Usmani, MD, FACP

What do you see for the future of myeloma treatment?

Joshua Richter, MD

MO Signup MailChimp
MedicalEd
Subscribe Today to join our
MedicalEd Digest
mailing list!

Your email address will not be shared with any third party, nor sold

Trending Now

Highlights in Multiple Myeloma from the Annual ASCO and EHA 2022 Meetings

Joshua Richter, MD

Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes

Sagar Lonial, MD, FACP and Saad Z. Usmani, MD, FACP

What are the new and notable findings from EHA and ASCO that are relevant to transplant eligible newly diagnosed multiple myeloma?

Joshua Richter, MD

What are the challenges and unmet needs associated with managing multiple myeloma today?

Joshua Richter, MD

What has been the overall impact of safety and efficacy in four-drug regimens compared to three-drug regimens?

Sagar Lonial, MD, FACP

Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?

Saad Z. Usmani, MD, FACP

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMDS.com | ManagingMPN.com | ManagingLymphoma.com | PracticalOncologist.com | MediComWorldwide.com

©2023 MediCom Worldwide, Inc. All rights reserved
  • Privacy, Terms, and Conditions
  • Contact Us